阿舒瑞韦 - Suppr | 超能文献

Asunaprevir.

出版信息

Aust Prescr. 2016 Apr;39(2):58-60. doi: 10.18773/austprescr.2016.009. Epub 2015 Nov 19.

DOI:10.18773/austprescr.2016.009

PMID:27340324

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4917633/

Abstract

摘要

相似文献

Asunaprevir.

Aust Prescr. 2016 Apr;39(2):58-60. doi: 10.18773/austprescr.2016.009. Epub 2015 Nov 19.

Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.

Clin Drug Investig. 2018 May;38(5):427-437. doi: 10.1007/s40261-018-0621-9.

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.

J Hepatol. 2014 Mar;60(3):490-9. doi: 10.1016/j.jhep.2013.10.019. Epub 2013 Oct 26.

Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.

J Gastroenterol Hepatol. 2017 Mar;32(3):645-650. doi: 10.1111/jgh.13511.

Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.

Value Health Reg Issues. 2017 May;12:1-6. doi: 10.1016/j.vhri.2016.10.002. Epub 2016 Dec 24.

Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.

Clin Pharmacol Drug Dev. 2019 Aug;8(6):802-817. doi: 10.1002/cpdd.649. Epub 2019 Jan 10.

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.

J Clin Pharmacol. 2018 Nov;58(11):1468-1478. doi: 10.1002/jcph.1274. Epub 2018 Jul 31.

Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus.

Front Microbiol. 2017 Apr 20;8:668. doi: 10.3389/fmicb.2017.00668. eCollection 2017.

Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.

Expert Rev Anti Infect Ther. 2015;13(11):1307-17. doi: 10.1586/14787210.2015.1091724. Epub 2015 Sep 28.

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Lancet. 2014 Nov 1;384(9954):1597-605. doi: 10.1016/S0140-6736(14)61059-X. Epub 2014 Jul 28.

本文引用的文献

Daclatasvir.

Aust Prescr. 2015 Dec;38(6):217-9. doi: 10.18773/austprescr.2015.077. Epub 2015 Oct 1.

Treating hepatitis C - what's new?

Aust Prescr. 2015 Dec;38(6):191-7. doi: 10.18773/austprescr.2015.068. Epub 2015 Sep 18.

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.

Clin Infect Dis. 2015 Sep 1;61(5):817-25. doi: 10.1093/cid/civ381. Epub 2015 May 14.

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

J Hepatol. 2015 Jul;63(1):30-7. doi: 10.1016/j.jhep.2015.02.018. Epub 2015 Feb 19.

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Lancet. 2014 Nov 1;384(9954):1597-605. doi: 10.1016/S0140-6736(14)61059-X. Epub 2014 Jul 28.

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Hepatology. 2014 Jun;59(6):2083-91. doi: 10.1002/hep.27113. Epub 2014 Apr 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Asunaprevir.

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献